Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of Funobactam (XNW4107) with Imipenem/Cilastatin in Renal Impairment
NCT04787562Phase 1Completed
- Sponsor
- Evopoint Biosciences
- Start
- Feb 2021
- Primary completion
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of pibozobactam in bacterial infection (5 arms), sponsored by Evopoint Biosciences. Primary endpoints: Total body clearance, Apparent steady-state volume of distribution and 4 more. Started Feb 2021; status: completed.
02
Drugs
pibozobactam
03
Conditions
bacterial infection
Beyond the preview
Go deeper on NCT04787562.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04787562.